LENZ rallies presbyopia awareness with eyecare professionals ahead of FDA submission

LENZ Ther­a­peu­tics is clear on the ben­e­fits of pre-com­mer­cial mar­ket­ing for its pres­by­opia eye drops, bol­stered by pos­i­tive Phase 3 news this week. The new da­ta back its con­fi­dence — and plans to file for FDA ap­proval midyear — in its late-stage can­di­date and main­stream mar­ket po­ten­tial.

The biotech soft-launched a cam­paign for eye care pro­fes­sion­als in Feb­ru­ary, and will ful­ly launch mid-month with the ad­di­tion of 30 more op­tom­e­try and oph­thal­mol­o­gy ex­perts join­ing the “Eye Am” ef­fort. The aware­ness web­site us­es strik­ing pho­tographs of lead­ing eye care doc­tors tak­en by com­mer­cial pho­tog­ra­ph­er and di­rec­tor Will Strawser, along with state­ments about the doc­tors’ ex­cite­ment and ex­pec­ta­tions around new pres­by­opia re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.